Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Wilms Tumor 9Prostatic Neoplasms 9Glioma 9Osteosarcoma 8Neuroblastoma 8Multiple Myeloma 8Leukemia, Myeloid, Acute 8Sarcoma 7Rhabdoid Tumor 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Lymphoma 6Lung Neoplasms 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Colorectal Neoplasms 6Breast Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Central Nervous System Neoplasms 5Carcinoma, Hepatocellular 5Sarcoma, Ewing 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3

Interventions

Temozolomide 41Magnetic Resonance Spectroscopy 19Radiotherapy 18Specimen Handling 14Radiation 12Bevacizumab 11Lomustine 9pembrolizumab 6fludarabine 5Surgical Procedures, Operative 5atezolizumab 4Nivolumab 4Ipilimumab 4Cyclophosphamide 4Carboplatin 4Biopsy 4cemiplimab 3azeliragon 3Immunoglobulin G 3Disulfides 3Aminolevulinic Acid 3veliparib 2trametinib 2rocakinogene sifuplasmid 2poly ICLC 2pamiparib 2olaparib 2lutetium Lu 177 dotatate 2durvalumab 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × X-Rays × 90 days × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡